Results 141 to 150 of about 4,772,082 (338)

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

open access: yesMolecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau   +9 more
wiley   +1 more source

Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes [PDF]

open access: yes, 1990
Although the relative contribution of different immune effector functions to clearing tissues of cytomegalovirus is controversial, the contribution of CD8+ T lymphocytes has generally been accepted as essential. In this report, we show that under certain
Jonjic, Stipan   +4 more
core  

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Impacts of Architectural Sights on Anxiety Relief in a High-Density City

open access: yesEngineering Proceedings
Due to rapid urbanization, high-density cities have become a dominant human habitat, and sustainable urban development has become a key concept in urban governance.
Yung-Chia Chiu   +3 more
doaj   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

POTENCY AND SAFETY TESTING OF HAEMORRHAGIC SEPTICAEMIA OIL ADJUVANTED VACCINE IN SWISS ALBINO MICE [PDF]

open access: yesPakistan Veterinary Journal, 2005
The present study was conducted to evaluate the potency and safety of haemorrhagic septicaemia oil adjuvant vaccine in Swiss albino mice via subcutaneous route of inoculation.
A. R. Bhatti, K. Tasneem, Z. J. Gill and A. Raza
doaj  

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. [PDF]

open access: yes, 1990
Breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a prerequisite for active or passive tumor-specific immunotherapy.
Koeppen, H   +5 more
core  

Home - About - Disclaimer - Privacy